Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg stays bullish on Ceres Power despite Bosch 'setback'

(Sharecast News) - Shares in Ceres Power have plummeted over the past week after Bosch ended a partnership with the firm and intends to sell its stake, though Berenberg said it still sees significant value to the stock despite the "setback". Bosch announced on 20 February that it will discontinue its operations relating to the industrialisation and preparation for production of decentralised power-supply systems based on solid oxide fuel cells, thus ending its partnership with Ceres.

As a result, the company also decided to divest its 17.44% shareholding in the company.

Berenberg has slashed its target price for Ceres from 650p to just 340p, but that still represents huge upside from Tuesday afternoon's price of 70.95p, with the shares having nearly halved since the news.

"While this was clearly a disappointing update for Ceres and it may take time to restore market confidence, we note that in the near term this has limited impact on our financial forecasts and, importantly, over the last 12-18 months, the company has signed partnerships with other global manufacturing partners that will help scale the technology over the long term," the broker said.

Nevertheless, looking further out, Berenberg has still cut its 2025-2030 revenue forecasts by a cumulative £150m or 25%.

"Overall, while the loss of Bosch is clearly frustrating, we remain confident in the ability of Ceres's partners to scale-up the technology and generate significant long-term, high-margin royalty revenue," the broker said, keeping a 'buy' rating on the stock.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.